News

Beam Global (BEEM) Q3 2025 Earnings Call Transcript

1 Mins read

Operator

Good afternoon, and welcome to the Beam Global Third Quarter 2025 Operating Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Lisa Potok, Chief Financial Officer. Please go ahead.

Lisa Potok
Chief Financial Officer

Good afternoon and thank you for participating in Beam Global’s Third Quarter 2025 Operating Results Conference Call this Friday afternoon. We appreciate you joining us today to hear an update on our business. Joining me is Desmond Wheatley, President, CEO and Chairman of Beam Global. Desmond will be providing an update on recent activities at Beam followed by a question-and-answer session.

But first, I’d like to communicate to you that during this call, management will be making forward-looking statements, including statements that address Beam’s expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Beam’s most recently filed Form 10-K and other periodic reports filed with the SEC.

The content of this call contains time-sensitive information that is accurate only as of today, November 14, ’25. Except as required by law, Beam disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. So next, I’d like to provide an overview of our financial results for Beam’s Q3 of 2025. For the third quarter

Read the full article here

Related posts
News

ZTR: Hybrid Portfolio With Utility Tilt At A Deep Discount (NYSE:ZTR)

1 Mins read
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds…
News

IJT ETF: Why The Tide May Turn For Small-Cap Growth In 2026 (NASDAQ:IJT)

1 Mins read
This article was written by Follow The Sunday Investor is focused exclusively on U.S. Equity ETFs. He has a strong analytical background,…
News

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

1 Mins read
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *